ea0099oc12.4 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024
Mathur Nitish
, Sharma Angelica
, Philip Nevil
, Rengarajan Lakshmi
, Bomphrey Lucy
, Abraham Anu
, Saraf Sanjay
, Dhatariya Ketan
, Kempegowda Punith
, Working Group Dekode
Background: Although SGLT2 inhibitors (SGLT2-i) have revolutionised the management of diabetes, they are associated with an increased risk of developing diabetic ketoacidosis (DKA). However, there remains a paucity of evidence about the risk factors, management, and outcomes of DKA episodes associated with SGLT2-i therapy. Improved understanding of these factors in order to optimise education, minimise risk, and improve outcomes of DKA episodes in individuals receiving SGLT2-i...